Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01718938 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis
A Phase 2 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01718938: Completed Phase 2 study, sponsored by Theravance Biopharma.
NCT01718938 is a Phase 2 study that has completed, run by Theravance Biopharma. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01718938, a Phase 2 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, incomplete block, three period fixed sequence crossover, multicenter, placebo-controlled study. The study will assess three oral doses of velusetrag (5 mg, 15 mg, and/or 30 mg) or placebo, administered once daily in three periods of 1-week duration each, with a 1-week washout period between treatment periods, in subjects with diabetic or idiopathic gastroparesis. Study 0093 will evaluate the effect of velusetrag in subjects with diabetic or idiopathic gastroparesis by assessing changes in gastric emptying.
Interventions
- DRUG placebo
- DRUG velusetrag dose 1
- DRUG velusetrag dose 2
- DRUG velusetrag dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT01718938 record still lists
NCT01718938 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT01718938 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01718938 about?
NCT01718938 is a clinical study titled "Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis". This is a multicenter, randomized, double-blind, incomplete block, three period fixed sequence crossover, multicenter, placebo-controlled study. The study will assess three oral doses of velusetrag (5 mg, 15 mg, and/or 30 mg) or placebo, administered once daily in three periods of 1-week duration ea...
What is the current status of trial NCT01718938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2012-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01718938?
The interventions under investigation include: placebo (DRUG), velusetrag dose 1 (DRUG), velusetrag dose 2 (DRUG), velusetrag dose 3 (DRUG).
Who is sponsoring clinical trial NCT01718938?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01718938's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia